N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder

Launched by YALE UNIVERSITY · Jul 28, 2010

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children aged 8-17 years.
• • Primary diagnosis of OCD.
• • Duration of OCD greater than 6 months.
• • Significant Current OCD symptoms: Current CY-BOCS score \> or = 16.
• Exclusion Criteria:
• • Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental disorder or mental retardation (IQ\<70).
• • Recent change (less than 4 weeks) in medications that have potential effects on OCD severity (such as Selective Serotonin Reuptake Inhibitors, clomipramine, naltrexone, lithium, psychostimulants, anxiolytics, or antipsychotics). Medication change is defined to include either dose changes or medication discontinuation.
• • Recent change in behavioral treatment for OCD or comorbid conditions within the last 4 weeks or initiation of behavioral therapy for tics within the last 12 weeks.
• • Asthma requiring medication use within the last 3 months (case reports have linked intravenous NAC administration with asthma exacerbation)
• • Known hypersensitivity or previous anaphylactoid reaction to acetylcysteine or any components in its preparation.
• • Positive pregnancy test or drug screening test.
• • Previous use of N-acetylcysteine (dose greater than 600mg for more than 2 weeks).
• • Previous history or suspicion of cystinuria because of a possibility of forming kidney stones.